InflaRx (NASDAQ:IFRX) Downgraded by Zacks Research to “Hold”

InflaRx (NASDAQ:IFRX) was downgraded by investment analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report released on Tuesday,Zacks.com reports.

Other analysts have also issued research reports about the company. Raymond James Financial upgraded InflaRx from an “outperform” rating to a “strong-buy” rating and increased their target price for the company from $7.00 to $9.00 in a report on Wednesday, May 13th. Cantor Fitzgerald lifted their price target on InflaRx from $4.00 to $6.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Wall Street Zen raised InflaRx from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of InflaRx in a research note on Wednesday, June 24th. Finally, HC Wainwright lifted their target price on InflaRx from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, May 11th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $7.33.

InflaRx Stock Down 1.6%

NASDAQ:IFRX opened at $2.42 on Tuesday. The business’s 50-day moving average price is $1.97 and its 200 day moving average price is $1.64. InflaRx has a 52-week low of $0.80 and a 52-week high of $2.95. The firm has a market cap of $356.64 million, a P/E ratio of -4.17 and a beta of 2.48.

InflaRx (NASDAQ:IFRX) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.04). Sell-side analysts expect that InflaRx will post -0.31 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of IFRX. Spruce Street Capital LP acquired a new stake in InflaRx in the 2nd quarter valued at approximately $11,988,924,000. ADAR1 Capital Management LLC acquired a new position in shares of InflaRx during the second quarter worth approximately $6,720,000. 683 Capital Management LLC lifted its holdings in shares of InflaRx by 47.3% during the fourth quarter. 683 Capital Management LLC now owns 3,315,000 shares of the company’s stock worth $3,348,000 after buying an additional 1,065,000 shares during the last quarter. Montanova Capital LLC boosted its position in shares of InflaRx by 189.1% in the second quarter. Montanova Capital LLC now owns 22,933,910 shares of the company’s stock valued at $51,372,000 after acquiring an additional 15,000,000 shares during the period. Finally, Jefferies Financial Group Inc. bought a new stake in shares of InflaRx in the second quarter valued at approximately $1,737,000. Institutional investors and hedge funds own 42.39% of the company’s stock.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.